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Abstract
A major purpose of treating patients with cystic ﬁbrosis (CF) is to prevent or delay chronic lung infections with CF-pathogenic Gram-negative
bacteria. In the intermittent stage, bacteria can usually be eradicated from the lungs with antibiotics, but following eradication, the next lung
colonisations often occur with bacteria of identical genotype. This may be due to re-colonisation from the patient’s paranasal sinuses. In our study,
we found that approximately two-thirds of CF patients having sinus surgery (FESS) had growth of CF-lung-pathogenic Gram-negative bacteria in
their sinuses (Pseudomonas aeruginosa , Achromobacter xylosoxidans , Burkholderia cepacia complex).
The environment in the sinuses is in many ways similar to that of the lower respiratory tract, e.g. low oxygen concentration in secretions. Sinus
bacteria are more difﬁcult to eradicate than in the lungs, thus, having good conditions for adapting to the environment in the lungs. In the presence
of bacteria, the environment of the sinuses differs from that of the lower respiratory tract by having a higher immunoglobulin A (IgA):IgG ratio, and
reduced inﬂammation. We found a signiﬁcant correlation between the concentration of IgA against P. aeruginosa (standard antigen and alginate)
in nasal secretions and saliva and CF patients’ infection status (not lung colonised, intermittently colonised or chronically lung-infected with
P. aeruginosa). This supports the hypothesis that infections often originate in the sinuses and can be a focus for initial lung colonisation or for
maintaining lung infections in CF patients. We are conﬁdent that anti-P. aeruginosa IgA can be used as an early supplementary tool to diagnose
P. aeruginosa colonisation; P. aeruginosa being the microorganism causing most morbidity and mortality in CF patients. This is important since
urgent treatment reduces morbidity when CF patients are early colonised with P. aeruginosa , however, there is a lack of diagnostic tools for
detecting the early colonisation in the lungs and in the sinuses.
We initiated a treatment strategy for CF patients to prevent sino-nasal bacteria being seeded into the lower airways: we recommended extensive
functional endoscopic FESS with creation of sufﬁcient drainage from all involved sinuses with subsequent i.v. antibiotics and at least 6 months
of twice daily nasal irrigation with saline and antibiotics. By this strategy, sinus bacteria could be eradicated in a large proportion of patients.
Essentially, growth of CF-pathogenic bacteria from the lower respiratory tract was decreased following the treatment. Furthermore, a number of
patients have been free from CF-pathogenic bacteria for more than one year after FESS, and thus re-classiﬁed as “not lung colonised”. We also
corroborated that CF patients obtain an improved quality of life and reduction in their symptoms of chronic rhinosinusitis after FESS.
It is primarily intermittently lung colonised CF patients with CF-pathogenic bacteria in their sinuses that seem to beneﬁt from the treatment strategy.
This is in accordance with the fact that we did not see a signiﬁcant increase in lung function and only a small decrease in speciﬁc antibodies after
FESS; a high systemic immune and inﬂammatory response and a decreasing lung function is generally not present in patients who primarily have
sinus CF-pathogenic bacteria.
It is important that guidelines are created for how CF patients with CF-pathogenic bacteria in the sinuses are to be treated, including criteria for
who may likely beneﬁt from FESS, and who may be treated exclusively with conservative therapy, e.g. saline and antibiotic irrigations.
© 2013 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.
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1. Introduction
There has been little focus on the paranasal sinuses in patients
with cystic ﬁbrosis (CF). However, our multidisciplinary group
has contributed to creating awareness about this important issue
during recent years and has published four studies on the topic
with a common thread combining basic, paraclinical and clinical
research [1–4].
1.1. Aims
I have focused on elucidating whether the paranasal sinuses
can be a focus for initial lung colonisations and whether it is
plausible that they also may serve as a focus for re-infections in
CF-patients. In detail, the aims are:
(a) Discuss the prevalence of bacteria found in the CF
sinuses [1–4].
(b) Put the sinusmucosal inﬂammation into perspective [1,2].
(c) Describe a potential new method of diagnosing CF
pathogen sinusitis; this will be a platform to discuss how
CF sinusitis may be identiﬁed and treated [2,3].
(d) Put forward a treatment strategy for CF patients with
pathogen sinusitis and discuss pros and cons for different
treatments of CF sinuses [3,4].
(e) Present and discuss results on how our treatment addressing
the sinuses inﬂuences lung colonisations and re-infections
and relate these to further studies [3,4].
2. Background
2.1. Cystic fibrosis (CF)
CF is a severe recessive genetic disease, which is common
among the Caucasian population. In Denmark, the incidence
is 1:4,700 [5]; the Faroe Islands having one of the highest
incidences in the world. Currently, approximately 450 patients
with CF are living in Denmark; one-third of the patients are
followed at the Cystic Fibrosis Centre in Århus while two-
thirds are followed at the Cystic Fibrosis Centre in Copenhagen
Rigshospitalet.
The disease is caused by mutations in the cystic ﬁbrosis
transmembrane conductance regulator protein (CFTR) located
on chromosome 7 [6]. The gene encodes the cAMP-dependent
chloride channel, and as a consequence of the defect, abnormal
transport of chloride and sodium across the cell epithelium
is seen, leading to reduced volume of epithelial lining ﬂuid
compared with non-CF individuals [7]. Thus, all secretions
contain a higher concentration of salt, which more than doubles
the viscosity compared with non-CF individuals [8].
The main clinical characteristics of CF are increased salt
loss in sweat, malabsorption, diabetes, male infertility, chronic
rhinosinusitis and increased fungal and viral airway infections;
most severe is the increased susceptibility to bacterial infections
of the lower airways.
2.2. Lower airways
Due to the viscous secretions, the mucocilliary clearance of
inhaled microbes is impaired making CF patients very suscepti-
ble to lower-airway infections [8,9]. From early childhood, the
infections are mostly caused by Haemophilus influenzae and
Staphylococcus aureus. When older, the CF-pathogenic Gram-
negative bacteria Achromobacter xylosoxidans , Burkholderia
cepacia complex and especially Pseudomonas aeruginosa are
more frequently seen.When reaching adulthood, the vast major-
ity of patients have been colonised or infected with one or more
of the three mentioned CF-pathogenic Gram-negative bacteria
responsible for most of themorbidity andmortality in CF [10].
The initial stage of “never been lung colonised” with CF-
pathogenic Gram-negative bacteria is often replaced by a stage
of intermittent colonisation before entering the ﬁnal stage of
chronic infection. In spite of a frequently and regularly intensive
antibiotic treatment [11], the bacteria are presumably constantly
present in some pulmonary segments when chronically infected.
The chronic stage is paraclinically characterised by constantly
high serum levels of immunoglobulin G (IgG) antibodies
and numerous polymorphonuclear leukocytes (PMNs) in the
lower airways. Elevated serum levels of speciﬁc antibodies
are also seen and are used as a supplementary diagnostic tool
(mentioned in subsections 2.2.1 and 2.5.1). Likewise, increased
numbers of PMNs are strongly correlated to poor lung function;
the imbalance between PMN-proteinases and their inhibitors
leads to impaired phagocytosis, T-cell and B-cell imbalance,
and lung tissue damage [12]. Thus, the onset age of chronic
lung infection with P. aeruginosa is correlated with the life
expectancy in CF patients [13].
Clinically, CF-patients with chronic bacterial lung infections
tend to have lower quality of life, lower body mass index
(BMI) and declining lung function measured by FEV1 (forced
expiratory volume in 1 second %-predicted) and FVC (forced
vital capacity %-predicted). The major purposes of treating
patients with CF are to prevent or delay chronic lung infections
and keep the lung function at a steady state. This goal is difﬁcult
to achieve, consequently, CF is the second largest group of lung-
transplanted recipients in Europe [14].
2.2.1. Grading of pulmonary infection
Years ago, there was no international consensus about the
consequences of Gram-negative chronic lung infections for
the progression and prognosis of CF lung disease. By an
epidemiological study of the respiratory tract microbiology, the
deﬁnition of different infection categories was introduced [15].
It was shown that high serum levels of precipitating antibodies
against P. aeruginosa were characteristic in chronically infected
patients and in patients harbouring mucoid strains [16], and
that high and rapidly increasing levels of antibodies correlated
with poor prognosis [13]. The antibody response was shown to
have high sensitivity and speciﬁcity for the early detection of
chronic P. aeruginosa lung infection and was included in the
following deﬁnition of chronic infection: persistent presence of
bacteria in six consecutive months, or less when combined with
the presence of elevated precipitating antibodies [7,13].
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Fig. 1. Bacteria causing chronic lung infection in CF patients at the Copenhagen CF Centre in 2008 (with permission from Christine Rønne Hansen).
Since 1974, our centre has used the Copenhagen crite-
ria [13,16], which grades pulmonary infection into three cate-
gories based on having 10–12 lower airway samples cultured
a year: (1) never colonised, (2) intermittently colonised, and
(3) chronically infected. These criteria cannot be applied inmost
CF centres outside Denmark, because the patients are not seen
as regularly as in Copenhagen and as only a few centres have
access to the antibody tests. Consequently, the Leeds criteria
were developed [17] and were shown to correlate well with
the Copenhagen criteria [18–20]. The advantage of using the
Copenhagen criteria when patients are seen on amonthly basis is
that they allow an earlier initiation of eradication ormaintenance
therapy, which improves lung function in both intermittently
colonised and chronically infected CF patients [19,21].
Based on the fact that most CF centres outside Denmark only see
their patients every third month, the following Leeds criteria are
used:
(1) Never infected : there has never been growth of any CF
related Gram-negative bacteria.
(2) Non-infected : no growth of any CF related Gram-negative
bacteria over 12 months.
(3) Intermittent colonisation : growth in >0% and 50% of
samples.
(4) Chronic infection : growth in >50% of a patient’s monthly
lower-airway samples.
2.3. Pseudomonas aeruginosa
Pseudomonas aeruginosa is a Gram-negative rod-shaped
bacterium frequently found in soil, water and man-made
environments (e.g. water pipes). It is an opportunistic pathogen
of immune-compromised individuals. It thrives not only in
normal atmospheres, but can adjust to hypoxic conditions as in
the sputum and sinus secretions of CF patients [22,23]. Partly
induced by oxygen radicals from the PMNs, someP. aeruginosa
mutate during the initial colonisation making them more suit-
able for a chronic infection. The most important bacterial gene
is mucA, which causes P. aeruginosa transition from a non-
mucoid to a mucoid-phenotype producing alginate and bioﬁlms.
Other important mutations or changes of phenotypes cause:
down-regulation of the cell-to-cell communication (quorum-
sensing; las and rhl genes); increase antibiotic resistance;
change colony morphology; reduce swimming, swarming and
twitching motility; growth advantages; modify immune system
tolerance; and increased protease production [24,25].
Lung infections with P. aeruginosa cause inﬂammation result-
ing in a systemic increase of IgG antibodies against polyvalent
P. aeruginosa antigen (Standard Antigen (St-Ag)) [26] and the
mucoid exopolysaccharide alginate (a bioﬁlm-matrix compo-
nent), which are highly characteristic of P. aeruginosa [27,28].
In addition to serum, speciﬁc antibodies are present in tears
and in the upper airways as saliva and sputum; IgA being
the dominant antibody at mucosal surfaces [28,29]. Prior to
our studies [1,2], research on IgA in nasal secretions from CF
patients has, to our knowledge, never been investigated.
2.4. Achromobacter xylosoxidans, Burkholderia cepacia
complex
In CF, most research has been done on P. aeruginosa ,
being the bacteria causing the majority of chronic infections
(Fig. 1). A. xylosoxidans and B. cepacia complex are less
prevalent but have similar negative impact on pulmonary
disease progression. They are expected to have similar adaptive
mechanisms as P. aeruginosa causing similar inﬂammation and
lung destruction [30]. These bacteria are also Gram-negative
rods. In contrast to P. aeruginosa , B. cepacia complex is
resistant to colistimethate sodium; P. aeruginosa is seldom pan-
resistant and can often be treated with oral antibiotics, which is
in contrast to A. xylosoxidans , which is difﬁcult to treat with
oral antibiotics and rapidly develops multi-resistance [31,32].
Patients can be infected with more than one Gram-negative
bacteria but the outcome of bacterium–bacterium interactions
are unknown.
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Fig. 2. The arrows show the supposed drainage pathways of the paranasal sinuses. In these CF patients the drainage seems to be occluded and the sinuses are partly
opaciﬁed.
2.5. Detection of CF-pathogenic Gram-negative bacteria
Early aggressive antibiotic treatment of the ﬁrst P. aeruginosa
colonisation is crucial in order to prevent or postpone chronic
lung infections and is also cost-beneﬁcial [11,33]. Thus, this
fact has increased the necessity of rapid and sensitive detection
techniques [34,35]. Serum antibody titres against alkaline
protease, elastase and exotoxin A are on average low when
P. aeruginosa is isolated from the respiratory tract for the ﬁrst
time [36] and early diagnosis is challenging [37]. In our clinic,
speciﬁc IgG and precipitating serum antibodies are used as
a supplementary tool for monitoring lung colonisations and
infections. Clinical and paraclinical outcomes, e.g. pulmonary
function tests, are also used in the detection of pulmonary
bacteria. Culturing lower airway samples is the one of the most
important tools in the detection. These samples are obtained
by coughed sputum, endolaryngeal suction in non-sputum
producers, induced sputum that increases the recovery rate of
P. aeruginosa [38], or by bronchoalveolar lavage (BAL) having
a lower degree of upper respiratory tract contamination [39].
Detection of CF-pathogenic bacteria from the upper airways is
discussed below.
2.5.1. Immune responses
Elevated levels of speciﬁc anti-Pseudomonas IgG antibodies,
measured by enzyme-linked immunosorbent assay (ELISA),
is a risk-indicator for developing chronic P. aeruginosa
infection [40]. Precipitating antibodies measured by crossed
immunoelectrophoresisis (CIE) is used as a supplementary
tool for diagnosing and predicting the outcome of lung
infections [41]. Precipitating antibodies remain within the
normal range (0–1) in most cases during intermittent lung
colonisation but rise during chronic infection. The antibody
response has previously been shown to be helpful in dis-
tinguishing between intermittently colonised and chronically
infected patients using the Copenhagen criteria mentioned in
subsection 2.2.1 [7,40,41].
2.6. Upper airways
2.6.1. Sinus anatomy
The paranasal sinuses are a group of air-ﬁlled-spaces: the
maxillary sinuses surrounding the nasal cavity, the frontal
sinuses placed in the forehead above the eyes, the ethmoidal
sinuses are many small sinuses between the orbits, and the
sphenoid sinuses are deep and posterior to the ethmoids.
The sinuses are lined by mucosa and produce mucus. The
drainage pathways are shown in Fig. 2. Unexplained, CF sino-
nasal anatomy very often divagates from non-CF patients.
Common ﬁndings are nasal congestion, polyposis, mucoceles,
mucopurulent material, medial bulging of the maxillary walls,
ostitis and hypoplasia or aplasia of the paranasal sinuses
especially of the frontal sinus [42–45].
2.6.2. Chronic rhinosinusitis
The hallmark of CF in the head and neck region is chronic
rhinosinusitis (CRS) and nasal polyps. There is no speciﬁc
deﬁnition on CRS in CF patients, so they follow the general
deﬁnition stated in the European position paper on rhinosinusitis
(EPOS) [46] shown in Table 1. However, nasal and sinus
mucosal disease is by deﬁnition present in patients with CF
because of defective CFTR-channels in the sinonasal mucosa,
as found in the lower CF airways [46]. The inﬂamed tissue
and viscous mucus results in a mechanical obstruction of the
sinus ostia [45,47]. Further, the vast majority of CF patients
have radiologic evidence of sinus disease [42,45,48–53], and
nasal polyposis becomes more common with age that has
been reported in varying prevalence with up to 50% of all
CF patients [48,52,54,55]. There are inconsistent results on
whether CF patients with nasal polyps and symptoms of CRS
can be correlated with a better lung function [56–59].
CF patients are likely to under-report their symptoms of CRS,
giving a false low share of CF patients with CRS by the
deﬁnitions in Table 1; approximately two-thirds of all CF
patients have impaired olfactory function [9]), and 81–86%
of CF patients fulﬁl the EPOS criteria for CRS (ref. [60]
and unpublished material by Berkhout et al .), which is in
contrast to the low 10–15% who complain about CRS without
speciﬁc questioning [45,48,61–63]. It is unknown whether the
CF patients who do not complain about CRS always were
asymptomatic, if they have adapted to their symptoms, or if
their CRS symptoms are overshadowed by more troublesome
symptoms from e.g. the lungs [45].
In general, non-CF patients with nasal polyposis being
otherwise healthy have been shown to score worse on quality
of life than patients with chronic obstructive pulmonary disease
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Table 1
CRS deﬁnition in non-CF patients a
Inﬂammation of the nose and the paranasal sinuses with two or more
symptoms for 12 weeks;
One should be
• nasal blockage
• obstruction
• congestion
• nasal discharge (anterior/posterior nasal drip)
Others
• facial pain/pressure
• reduction of smell
Furthermore, demonstrable disease; at least one of following:
• nasal polyps
• mucopurulent discharge
• oedema/mucosal obstruction
• CT changes
• mucosal changes within the ostiomeatal complex and/or sinuses
a Adapted from the European position paper on rhinosinusitis and nasal
polyps 2012 [46].
and patients with coronary artery disease [64,65]. This ought to
give food for thought as to why symptoms of CRS should not
be neglected in CF patients. RSOM-31 and SNOT-22 [64,66]
are both questionnaires that are recommended outcome tools
for adult CRS and can easily be used, while the SN-5
questionnaire [67] is recommended for paediatric CRS [46].
2.6.3. Bacteriology of the upper airways
In non-CF patients, the paranasal sinuses are regarded as sterile
though they may be frequently and transiently contaminated
by bacteria from neighbouring surfaces [68]. CRS in otherwise
healthy individuals predominantly has viruses as a part of
the aetiology. When bacteria are involved, the following
species are most frequently cultured: Staphylococcus aureus,
Streptococcus pneumoniae, Streptococcus pyogenes gr. A,
Haemophilus influenzae andMoraxella catarrhalis [69,70]. In
CF patients, the picture is somewhat different. Sinus bacteria
are more frequently present, P. aeruginosa being the most
common as in the lungs. Other frequently found bacteria are
S. aureus, H. influenzae and coagulase-negative staphylococci;
anaerobes and other bacteria found in the lower airways such
as A. xylosoxidans and B. cepacia complex are also found
in the CF sinuses [44,53,70–76]. Presence of sinus bacteria is
reported in 44–95% [62,73,76]. Two articles have described
fungal sinusitis among North American CF patients but disagree
on the prevalence (0–33%) [74,76].
Though it has not been addressed, it is likely that the sinus
bacteria in CF patients also produce bioﬁlms that further
increase antibiotic resistance in the same way as in the non-
CF patients [24,70,77,78]. As in the lungs, the sinus bacteria
develop phenotypes that are resistant to the host immune
response and antibiotic treatment.
2.7. United airways in CF patients
A marked association exists between upper and lower airway
cultures in patients with CF [1,24,46,71,75,76,79–86] due to
the paranasal sinuses often being colonised with concordant
CF-lung-pathogenic Gram-negative bacteria of the same geno-
type [1,24,53]. Varying predictive values of CF-pathogenic
bacteria in the upper airways have been reported when
diagnosing lower airway pathogens [62,71,75,83].
A CF patient’s initial lung colonisation with P. aeruginosa re-
ﬂects the great diversity of genotypes in the environment, being
in contrast to some patients who, after antibiotic eradication,
subsequently are re-colonised with bacteria that are clonally
related [71,87–89]. This indicates that the initial bacteria come
from environmental sources rather from transmission between
patients [90] and an existence of a bacterial reservoir in the
patients’ close environment after the initial colonisation. This
reservoir is likely to be the sinuses where the bacteria can
drain/migrate/be aspirated to the lower airways as seen with
viruses [24,91].
The environment of the sinuses and the lower airways are simi-
lar in many ways [22,23,46], thus the sinuses may be colonised
with bacteria before the lungs and be an evolutionary ‘nest’ in
early airway colonisations, where the bacteria are diversifying,
evolving antibiotic resistance and other phenotypes associated
with adaptation to the CF airways in general; from there, the
bacteria intermittently migrate and colonise the lungs and may
ultimately cause chronic lung infections [1,23,24,71,76]. When
bacteria colonise the lungs they are then pre-adapted to the
environment and are therefore less virulent and more resistant
compared with environmental P. aeruginosa isolates [24].
This also accounts for lung transplanted (LTX) CF patients,
where molecular epidemiology studies have shown that CF
lung-transplant recipients become re-colonised in their lung
grafts with the same bacterial clones as those cultured before
transplantation [86].
One study has shown that CF-lung-pathogenic bacteria po-
tentially can be eradicated from the sinuses with extensive
functional endonasal endoscopic sinus surgery (FESS) and
postoperative local antibiotic treatment [92]. Nevertheless,
large-scale prospective studies investigating the effects of FESS
on lung colonisation and infection in CF are lacking [46], and
data on surgical therapy for CF patients with CRS is primarily
based on level III evidence (Table 2) [46,93].
Several studies have described the effect of FESS on the lower
airways using various parameters and treatment modalities, thus
showing inconsistent results (Table 3). One prospective study
has performed extensive FESS intending to eradicate sinus
bacteria in a group of 82 LTX patients, which is described
in three papers [92,94,95], showing that P. aeruginosa and
A. xylosoxidans could be eradicated from the sinuses resulting
in reduced lung allograft infections. Shatz [96] found decreased
antibiotic use, a lower hospitalisation rate and an increase in
FEV1 six months after FESS among 15 CF non-LTX patients.
Lewiston et al. [97] postoperatively installed tobramycin di-
rectly into the sinuses and reported a lower rate of P. aeruginosa
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Table 2
Categories of evidence [98]
Category Deﬁnition
Ia Evidence from meta-analysis of randomised controlled trials.
Ib Evidence from at least one randomised controlled trial.
IIa Evidence from at least one controlled study without randomisation.
IIb Evidence from at least one other type of quasi-experimental study.
III Evidence from non-experimental descriptive studies, such as
comparative studies, correlation studies and case control studies.
IV Evidence from expert committees’ reports or opinions and/or
clinical experience of respected authorities.
in the lungs among 11 LTX patients. The other retrospective
studies were all based on moderate sinus surgery, and did not
focus on lung infection status or a protocol for postoperative
treatment. These studies found inconsistent postoperative
reduction in lung colonisation, lower hospitalisation rates,
reduced use of antibiotics and improvement of the pulmonary
function tests (PFT). Table 3 shows an overview of the published
papers on sinus surgery in relation to the lungs; none of the
studies are level I evidence (Table 2).
2.8. Assessment of the upper CF airways
2.8.1. Imaging
The radiation dose of one CT scan of the paranasal sinuses is
now reduced to only 0.5–1.0mSv (in comparison, the Danish
annual radiation dose varies from 2–20mSv). Imaging of the
sinuses is mandatory for planning surgical interventions but
should not be performed abundantly, thus, CT scans have
a low diagnostic value in CF patients [53,61,109]. Magnetic
resonance imaging (MRI) allows better differentiation of
mucosa, polyps and retained secretions but does not display
osseous structures bordering the orbit and brain [50,110].
Imaging is mandatory prior to FESS due to the altered and
varying anatomy of the sinuses with relation to the orbit, brain
and major vessels (see subsection 2.6.1). The capacity for doing
MRI is restricted at our institution, which is why solely CT scans
are used.
2.8.2. Culture
Although sinus aspiration is the gold standard for the diagnosis
of bacterial sinusitis, it is an invasive, time-consuming and
potentially painful procedure [68,111]. The diagnostic accuracy
of oropharyngeal swab cultures is low in predicting P. aeru-
ginosa sinusitis, particularly at younger ages (positive and
negative predictive values: 73% and 72%) [62]. Cultures of
endoscopically collectedmiddlemeatus secretions is reported as
effective in identifying microorganisms in non-CF CRS patients
and in CF patients [112]. However, nasal irrigations are also
suggested as a preferable technique over nasal swabs to obtain
samples from the upper airways in CF patients [71].
2.8.3. Steroids
A Cochrane review states that oral corticosteroids appear to
slow progression of lung disease in CF [113]. However, no
research is published on oral steroids’ effect on CRS symptoms
in CF patients, while one study recommends intrapolyp steroid
injection [114]. Another Cochrane review states that: “Overall,
there is no clear evidence for using topical steroids in people
with CF and nasal polyposis”. This is due to the neutrophilic
domination in CF polyposis compared with the eosinophil
domination in non-CF patients [115]. However, it should be
mentioned that some studies report a positive effect of using
nasal steroids on CRS and nasal polyps in CF [116–118].
2.8.4. Surgery
In 2006, a Cochrane review concluded that more randomize
controlled trials comparing FESS with other treatments were
required, thus it could not be conﬁrmed that CF patients with
CRS symptoms could beneﬁt from FESS [93]. The newest
edition of EPOS 2012 and other recent studies state that symp-
toms of nasal airway obstruction, nasal discharge, facial pain,
snoring, olfactory dysfunction, frequency of sinus infections
and activity level are parameters that can signiﬁcantly be
improved after FESS in CF patients [46,107,119–124]. When
evaluating the different studies, it is important to note the criteria
for FESS and what FESS and postoperative treatment comprise.
In spite of postoperative instrumental debridement and saline
irrigations [121,125], it is accepted that the effect of FESS on
CRS symptoms, in general, lasts a shorter time in CF patients
than in non-CF patients [57,104,107,121,122,124], which is
why a more extensive approach has been suggested [82,126–
130] combined with antibiotic sinus irrigations [72]. As in
any other surgery, FESS involves risks. Though they are rare,
situations where the optic nerve or brain is damaged and
extensive bleeding can occur. Nevertheless, when surgeons are
aware of the altered anatomy in CF patients (described in
subsection 2.6.1), reports show that FESS is well tolerated and
that the complication rate in CF patients is similar to that of the
non-CF population [46,104,131].
2.8.5. Local treatment
Nasal saline irrigations are well tolerated and the beneﬁcial
effect appears to outweigh the minor side effects, thus they
can be included as a treatment adjunct for the symptoms
of CRS in CF-patients [46,132]. Hypertonic saline 7% may
have mucolytic effects and improve mucociliary clearance in
the sinuses as seen in the lungs of CF patients and may be
used for nasal irrigations [133–135]. Baby shampoo is also
introduced as a supplement to the saline [136,137], as is nasal
inhalation of dornase alfa used in the treatment of CRS in CF
patients [138–140]. Studies of nasal irrigations with antibiotics
(tobramycin or aminoglycosides) show decreased bacterial
colonisation and nasal inﬂammation and a positive effect on
recurrence rate of CRS in non-CF patients [141]. However,
there is low-level evidence for the use of topical anti-bacterials
in CF patients [46,142]. Several devices including nebulizers
have been developed for nasal irrigations and distribution
of medicine [139,143], which are all better than delivering
it by nasal spray [46]. Finally, low-frequency ultrasound has
recently been suggested as a supplementary method for bioﬁlm
disruption in patients with CRS [144].
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3. Material
3.1. Study population
In our four studies [1–4], patients were recruited among the
300 CF patients treated at the CF Centre in Copenhagen. The
diagnosis of CF was based on clinical characteristics, abnormal
sweat electrolytes, and genotype. CF patients followed a routine
protocol with monthly medical examinations including lung
function tests and lower airway samples taken for microbio-
logical culture. Additional lower airway samples were taken
whenever patients were hospitalised or when clinical and/or
paraclinical parameters indicated a risk of lung colonisation
or infection. Approximately every third month, blood samples
were taken for analyses including speciﬁc antibodies against
relevant Gram-negative bacteria [41]. LTX patients followed a
different outpatient setting with fewer routine samples taken.
All CF pathogens were treated with antibiotics regardless of
clinical symptoms according to the Copenhagen CF Centre’s
treatment protocols [11].
3.2. Usage of different grading of pulmonary infections
Asmentioned in subsection 2.2.1, there are at least two different
ways of grading pulmonary infections. In our studies reported
in refs. [1] and [2], we applied our standard Copenhagen
criteria for deﬁning lung infection status and LTX patients were
categorised as chronically infected.
Modiﬁed Leeds criteria [17] were used for deﬁning lung
infection status in our studies [3,4]; as lung infection status
was the main outcome in the study reported in ref. [4], it was
important to use simple criteria here that are known and can be
used among other CF centres. This facilitates an international
comparison in the future. Secondly, the use of the Leeds
criteria allowed us to put our ﬁndings into perspective because
intermittently colonised patients could be re-classiﬁed as non-
infected. Thirdly, a rise in antibodies was, in some cases, a part
of the reason for setting patients up for surgery (described in
subsection 4.1.1), and so it would be a circular argument if
antibodieswere also used to deﬁne the outcome of lung infection
status.
4. Methods
4.1. Functional endoscopic sinus surgery (FESS)
4.1.1. Criteria for FESS
FESS (Fig. 3) was a part of the studies reported in refs. [1], [3]
and [4]. CF patients were selected for FESS based on the
following criteria:
(1) Search for an infectious focus: Intermittently colonised
patients with increasing frequency of positive lower airway
cultures or repeatedly declining lung function (>10%),
despite intensive antibiotic chemotherapy. Patients with an
unknown infectious focus and increasing antibodies against
P. aeruginosa, A. xylosoxidans or B. cepacia complex were
given the highest priority.
Fig. 3. Set-up for FESS.
(2) Patients who had recently been LTX. The ambition was to
perform FESS within the ﬁrst postoperative year.
(3) Patients with severe symptoms of chronic rhinosinusitis
(CRS) according to the EPOS [46].
4.1.2. FESS procedure
A BAL was performed under general anaesthetic. The subse-
quent FESS was to ventilate and drain the paranasal sinuses
and to make these accessible for postoperative instrumental
cleansing and irrigation with saline and topical antibiotics. Each
patient was evaluated for symptoms of chronic rhinosinusi-
tis [46] followed by a clinical examination. The extension of
surgery (e.g., exploration of the frontal or sphenoid sinuses) was
undertaken based on the preoperative CT scan and perioperative
ﬁndings. As a standard, we applied FESS with an uncinectomy,
an anterior ethmoidectomy and a medial antrostomy, leaving a
signiﬁcantly enlarged maxillary ostium comprising more than
half the medial maxillary wall as recommended [46]. Visible
intramucosal abscess-like structures (especially found in the
maxillary sinuses) were resected along with other inﬂamed
mucosal tissue when accessible. Finally, the opened and now
accessible sinuses were irrigated with saline and colistimethate
sodium.
To optimize culture results, no patients received i.v. antibiotics
within two weeks prior to FESS, and different anatomic
Fig. 4. Pus containing P. aeruginosa exiting the left maxillary sinus before
FESS.
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Fig. 5. A view in the maxillary sinus.
Fig. 6. Material obtained for culture.
sampling locations and multiple samples for culture were
prioritized during surgery, including: nasal secretions, pus,
mucosa, polyps, and bone (Figs. 4–6). Samples taken for culture
were collected with sharp instruments or by suction tubes. The
material obtained was immediately cultured at the Department
of Clinical Microbiology at Rigshospitalet.
Fig. 7. Postoperative cleansing and culturing without use of local anaesthesia.
(Thanks to 7-year-old Jonas; a fantastic young man.)
4.1.3. Postoperative treatment
Postoperative adjuvant therapy included: two weeks of i.v.
antibiotics if there was the slightest suspicion that the lungs
or sinuses contained CF-pathogens [11], at least 6 months
of twice daily nasal irrigation with saline and antibiotics
(starting Day 1 with colistimethate sodium but could be
adjusted according to susceptibility), and 12 months of topical
nasal steroids (mometasonfuroate). As a standard each patient
had four postoperative visits to the oto-rhino-laryngologist
(ORL) outpatient clinic: one week and one, three and twelve
months postoperatively, where crusts and secretions were
endoscopically cleansed from the nasal cavities and sinuses
(Fig. 7). At each follow-up, under endoscopic guidance, the
patients were bilaterally cultured.
4.2. Culture methods
In our four studies reported in [1–4] the bacteriology of the
lungs and sinuses play a major role, thus the method of culture
is described in detail:
Gram-stained smears and aerobic cultures on selective media
were performed on all samples (Figs. 8, 9). These media
included a Sabouraud plate (for fungal growth), a 7% NaCl
plate, a B. cepacia plate containing Colistin and Gentamicin,
a “blue plate” (modiﬁed Conradi Drigalski’s medium) selective
for Gram-negative rods, and two non-selective media including
5% Danish blood agar and chocolate agar. In order to avoid
sampling bias, bacteria with different susceptibility patterns
and different colony morphologies were chosen and identiﬁed
as previously described [145,146]. In our study reported in
ref. [1], Gram-stained smears were used for bioﬁlm detection
and Pulsed Field Gel Electrophoresis (PFGE) was used for
genotyping P. aeruginosa isolates from the sinuses and the
lungs [146].
Fig. 8. Smears on selective media for culturing.
Fig. 9. (a) Growth of mucoid P. aeruginosa on a blue plate. (b) Antibiotic
susceptibility testing of P. aeruginosa .
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4.3. IgA and IgG antibodies against P. aeruginosa
In papers [1] and [2] we present and use a new method to
diagnose antibodies against P. aeruginosa St-Ag and alginate:
Twelve 6mm in diameter paper discs (Fig. 10) with obtained
serum or eluates of saliva or nasal secretions from each
patient were examined for IgA and IgG antibodies against
P. aeruginosa alginate and P. aeruginosa sonicate (St-Ag)
(serogroups 1–17) using enzyme-linked immunosorbent assays
(ELISA) as reported previously by our group [28,29]: Saliva
and nasal secretion impregnated paper-discs were incubated on
a shaker in dilution buffer to elute IgG and IgA antibodies.
Phosphate-buffered saline +0.1% Tween-20 +NaCl 15 g/l was
used for dilution, and the plates were washed three times
with it.
Fig. 10. A paper disc to collect secretions inserted in the nasal cavity.
4.3.1. Antibodies against P. aeruginosa alginate
Microtiter plates were coated with alginate puriﬁed from a
mucoid CF P. aeruginosa strain as previously reported by our
group [147]. The plates were coated and blocked in dilution
buffer. Diluted serum, saliva and nasal secretions (see above)
were added and allowed to react. After washing, horseradish
peroxidase (HRP)-conjugated rabbit anti-human IgA (P0216)
and anti-human IgG (P0214) were added and reacted.
4.3.2. Antibodies against P. aeruginosa St-Ag
A sonicated cell extract of P. aeruginosa serogroups 1–17
was used as standard St-Ag [28,29] and coated onto irrigated
96-well polystyrene plates. The plates were incubated and
blocked with dilution buffer. Serum, saliva, and nasal secretion
were diluted and allowed to react. After washing, horseradish
peroxidase (HRP)-conjugated rabbit anti-human IgA (P0216)
and anti-human IgG were added and left to react.
Fig. 11. ELISA procedures quantifying IgA and IgG in nasal and saliva
secretions as well as serum.
4.3.3. ELISA
For all ELISAs, TMB-Plus media was added. The reactions
were stopped after one hour at room temperature by adding
1M H2SO4. The absorbance was measured at 450 nm on a plate
reader. The results were expressed as optical density values
(OD) (Fig. 11).
4.4. Additional methods
The following well-established methods were used in our
studies: traditional immunohistochemistry in paper [2]; lung
function test [148,149], body mass index standard deviation
scores [150], speciﬁc anti-Pseudomonas IgG antibodies mea-
sured by ELISA [40] and precipitating antibodies measured by
CIE [41] are all regularly used when evaluating the CF patients
conditions, and were used in paper [4]. The CFQ-R (Cystic
Fibrosis Questionnaire-Revised) has also recently been initiated
in the CF centre to estimate the disease-speciﬁc health-related
qualify of life [151], thus was logical to use in paper [4].
The sinonasal outcome test (SNOT-22, Table 4) used in
paper [4] deals with sinonasal conditions [66], but also includes
health-related questions that can be inﬂuenced by other CF-
related conditions, e.g. cough; the SNOT-22 questionnaire is
used worldwide when evaluating CRS.
4.5. Statistics
In all four papers [1–4], we tested whether data were continuous
and if the comparisons fulﬁlled the criteria for normality and
equal variance. The level of signiﬁcance was set to0.05 (two-
tailed). SAS 9.1.3 was used for calculations.
In paper [1], the non-parametric sign test was used to compare
within patient samples of antibodies, while the data of
the antibodies in paper [2] were unpaired, continuous and
positively skewed distributed why Log10 transformations were
made. The transformed data had an approximately normal
distribution justifying an unpaired two-sample t-test for the
means and a one way analysis of variance (ANOVA).
Receiver operating characteristic (ROC) curves was used to ﬁnd
the best cut-off values between the three lung infection groups
if IgA was to be used as a diagnostic test [2]. A Spearman rank
coefﬁcient test was used to correlate nasal secretions and saliva
in [2] as well.
A McNemar’s test was used to compare the nominal data
of postoperative frequencies of growth with the perioperative
frequencies in paper [3] and to compare the change in lung
infection status after FESS (paper [4]). In paper [4], a paired
two-sample t-test for the means and an ANOVA was used for
the rest of the comparisons.
The biggest statistical challenge was in paper [4]. When
planning the study, we received statistical advice from Professor
Torben Martinussen at the Department of Biostatistics in how
to quantify the frequencies of positive cultures. The conclusion
was that every lower-airway sample was registered and given
the same weight regardless of the interval between the samples.
Using a Spearman rank coefﬁcient test, these results were then
compared to the results of lower-airways samples where each
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Table 4
SNOT-22 questionnaire [66]
1. Need to blow nose 0 1 2 3 4 5
2. Sneezing 0 1 2 3 4 5
3. Runny nose 0 1 2 3 4 5
4. Cough 0 1 2 3 4 5
5. Postnasal discharge (dripping at the back of your throat) 0 1 2 3 4 5
6. Thick nasal discharge (snot) 0 1 2 3 4 5
7. Ear fullness 0 1 2 3 4 5
8. Dizziness 0 1 2 3 4 5
9. Ear pain 0 1 2 3 4 5
10. Facial pain/pressure 0 1 2 3 4 5
11. Nasal blokage 0 1 2 3 4 5
12. Loss of taste and or smell 0 1 2 3 4 5
13. Difﬁculty falling asleep 0 1 2 3 4 5
14. Waking up at night 0 1 2 3 4 5
15. Lack of a good night’s sleep 0 1 2 3 4 5
16. Waking up tired 0 1 2 3 4 5
17. Fatigue 0 1 2 3 4 5
18. Reduced productivity 0 1 2 3 4 5
19. Reduced concentration 0 1 2 3 4 5
20. Frustrated/restless/irritable 0 1 2 3 4 5
21. Sad 0 1 2 3 4 5
22. Embarrassed 0 1 2 3 4 5
0 = no problem; 1 = very mild problem; 2 = mild or slight problem; 3 = moderate problem; 4 = severe problem;
5 = problem as bad as it can be.
Please mark the most important items affecting your health (maximum of 5 items).
culture was given weight according to the period until the next
culture.
4.6. Ethics
The study was approved by the local ethics committee (H-A-
2008-141), and all patients gave informed consent. In patients
<18 years of age, consent was also obtained from their parents.
The inclusion for FESS was not a part of the study, solely
the outcome. We also obtained consent for doing additional
analyses on the bacteria/material obtained during FESS and
BAL, the postoperative treatment and culturing, as well as for
using questionnaires and data from the patient ﬁles. In paper [2],
consent was used in order to obtain and analyze secretions and
blood and for culturing; no change in treatment modality was
made on behalf of these results.
5. Review of results
We found that the vast majority of CF patients have bacteria
in their paranasal sinuses [1–4]. They are often colonised with
CF-lung pathogens, especially P. aeruginosa , and there is a
close correlation between the bacteriology of the sinuses and
the lungs, including identical genotypes in the sinuses and
lungs [1,2,4]). Importantly, the genotype remains unchanged
over time. The chronically infected patients had the same
P. aeruginosa genotype in their lungs for a median of 15 years
as found in their sinuses, and up to 6 years in intermittently
colonised patients, although the bacteria apparently had been
eradicated from the lungs [1]).
Though the environment of the sinuses in many ways is
similar to that of the lower airways, including anaerobic niches
and bioﬁlm formation, it differs by excessive presence of
the non-phlogistic (does not induce inﬂammation) secretory-
immunoglobulin A (s-IgA) [1,2]. Failure to eradicate CF-
pathogens from the sinuses is probably a result of an inefﬁcient
local immune response: locally produced speciﬁc s-IgA binds
Gram-negative bacteria on the mucosal surface, thereby
reducing the inﬂammatory response by preventing antigen
presentation inhibiting complement activation, inhibiting the
recruitment of PMNs and thereby diminishing the oxidative
burst [1]). This was visualized by immunohistochemistry
showing excessive amounts of IgA-producing plasma cells in
the sino-nasal tissue and IgA in the excretory ducts. It was also
visualized by Gram-stained smears from the sinuses, where the
bacterial bioﬁlms were surrounded by very few and scattered
PMNs in marked contrast to the pulmonary ﬁndings [1,2]).
With this background information, our new method to quantify
IgA and IgG against P. aeruginosa antigen and against the
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Table 5
Mean nasal and serum antibodies against P. aeruginosa a
Nasal IgA Serum IgA Nasal IgG Serum IgG
Nasal IgA
Serum IgA
Nasal IgG
Serum IgG
Nasal
IgA
IgG
Serum
IgA
IgG
Non-CF controls (n = 9)
Alginate 0.17 0.05 0.09 0.12 3.29 0.92 2.19 0.57
St-Ag 0.63 0.51 0.28 0.96 1.74 0.24 2.93 0.56
Free from pathogenic bacteria (n = 32)
Alginate 0.28* (0.20) 0.13 (0.08) 0.09* (0.05) 0.12* (0.09) 2.57* (1.83) 0.84* (0.40) 3.72 (2.71) 1.24* (0.75)
St-Ag 0.77* (0.28) 0.73* (0.57) 0.19* (0.13) 1.01* (0.45) 1.99 (2.28) 0.19* (0.13) 5.94* (4.85) 0.66 (0.34)
Intermittent PA (n = 24)
Alginate 1.03 (0.68) 0.14 (0.14) 0.50 (0.50) 0.30 (0.26) 27.92 (83.42) 2.80 (3.64) 4.54 (5.24) 0.68 (0.67)
St-Ag 1.33 (0.35) 1.21 (0.87) 0.64 (0.59) 1.68 (0.64) 1.99 (1.87) 0.38 (0.27) 5.02 (6.58) 0.67 (0.34)
Chronic PA (n = 25)
Alginate 1.70* (0.60) 0.45* (0.31) 0.63* (0.50) 0.85* (0.71) 4.84* (2.79) 1.16 (1.41) 4.35 (3.76) 0.82 (0.78)
St-Ag 1.46 (0.47) 1.65 (0.68) 0.96* (0.41) 2.52* (0.77) 1.06* (0.58) 0.38 (0.16) 1.81* (1.07) 0.66 (0.26)
a Standard deviations are shown in brackets. The ratios were ﬁrst calculated for each individual and following the mean values were calculated.
P. aeruginosa-speciﬁc extracellular polysaccharide alginate,
was used to compare nasal, saliva and serum concentrations
with the patients’ lung infection status (described in sub-
section 2.2.1) in a cross-sectional study [2]). A signiﬁcant
correlation (p< 0.01) was found between the P. aeruginosa
lung infection status and the quantity of speciﬁc IgA in the
nasal secretions and saliva; the intermittently colonised patients
had the higher IgA concentrations than the non-infected patients
(Table 5). This test may then be used as a supplementary tool for
detecting CF patients with early lung colonisation. The theory
background and our results indicate that the test actually reveals
a P. aeruginosa-sinusitis, which again is a surrogate marker for
lung infections due to the concordant bacteria in the upper and
lower airways. In an upcoming prospective study we hope that
the usefulness of the IgA test as a marker of P. aeruginosa
sinusitis can be veriﬁed and that it will show a similar good
sensitivity and negative predictive value as was the case when
related to the lung infection status (Table 6).
Table 6
Combined nasal IgA St-Ag and alginate used to diagnose P. aeruginosa
lung colonisation
96% Sensitivity 81% Speciﬁcity
79% Positive predictive value 23 patients
True positive
6 patients
False positive
96% Negative predictive value 1 patient
False negative
26 patients
True negative
Sinus infectionswith CF-pathogens do not seem to be eradicated
by the frequent oral and intravenous antibiotic therapies that
CF patients receive. Conversely, in a prospective follow-
up study [3] P. aeruginosa, A. xylosoxidans and B. cepacia
complex could, in several cases, be eradicated from the sinuses
or the quantity of colony-forming units were at least reduced,
so the bacteria could not be re-detected by thorough sinus
cultures for several months (Table 7). This was achieved by
extensive sinus surgery and postoperative treatment (described
in subsection 4.1.2). Achieving these results was a prerequisite
for doing the research in our study reported in [4].
By the same procedure, probably as a consequence of the
sinus bacteria being eradicated, a signiﬁcant reduction in
frequencies of lower-airway cultures with CF-pathogens was
accomplished [4]. In particular, intermittently colonised CF
patients with concordant CF-pathogens in the sinuses seem
to beneﬁt from the treatment strategy. As a consequence, the
one-year prevalence of intermittent colonisation decreased by
38% after FESS and the one-year prevalence of non-colonised
patients increased by 150% (Table 8). In addition, speciﬁc
IgG for P. aeruginosa decreased and quality of life including
sinonasal symptoms also improved. This was shown by a
prospective, non-randomised, uncontrolled, intervention cohort
study [4].
Table 7
Cultures from the left and right sides of the middle meatus and maxillary sinus perioperative and at follow-up. In conclusion,
21 patients had no re-growth at any time at any sinus during six months of follow-up.
Lung status at surgery Perioperative One month Three months Six months Twelve months
LTX 24/24 (100%) 8/24 (33%) 9/20 (45%) 11/22 (50%) 9/20 (45%)
Chronically infected 25/26 (96%) 8/24 (33%) 12/24 (50%) 13/26 (50%) 8/18 (44%)
Intermittently colonised 55/66 (83%) 5/60 (8%) 11/60 (18%) 8/50 (16%) 12/48 (25%)
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Table 8
Lung infection status (as described in subsection 2.2.1) in the CF patients at FESS and a year after FESS and adjuvant therapy
Main lung bacteria Non-infected
Before FESS After FESS
Intermittently colonised
Before FESS After FESS
Chronically infected
Before FESS After FESS
P. aeruginosa 50 31 20 20
A. xylosoxidans 9 6 7 5
B. cepacia complex 2 1 2 3
Total 16 40 61 38 29 28
6. Discussion
Bacterial sinusitis being a focus for lung colonisation and
infection is supported by our ﬁnding of nearly all CF patients
having bacteria in their sinuses and by frequent lower-airway
cultures with CF-pathogens (P. aeruginosa, A. xylosoxidans ,
B. cepacia complex) correlating with a high frequency of
concordant bacteriology in the sinuses. In our patients selected
for FESS, 67% had concordant CF-pathogenic bacteria in the
sinuses and lungs and additionally 5% had CF-pathogens in
the sinuses that were not found in the lungs [4]. The high
prevalence of bacterial sinusitis is despite massive intravenous
and oral antibiotic treatment. Additionally, we often did
not get any positive lower-airway cultures during BAL in
intermittently lung-colonised patients even when we found CF-
pathogens in the sinuses; this indicates that the sinuses are a
more permanent focus than the lower airways. Our described
prevalence of bacterial sinusitis is at the high end compared
with other studies describing CF-sinus bacteriology (described
in subsection 2.6.3), which is probably a result of our invasive
and multiple-sample selection. Above all, we consider the risk
of false positive results very small; the only way that samples
can be cross-contaminated is via the anterior nasal cavity.
Few anaerobes and few fungus isolates were found in the
sinuses. Anaerobes were found when doing molecular studies
(unpublishedmaterial) but not even here were fungus frequently
found. This is in contrast to our expectations, as CF-patients
experience pulmonary problemswith fungus and one study cited
by EPOS found a high prevalence [46,74,152]. However, our
ﬁndings are in accordance with the general low prevalence of
fungus-sinusitis in Danish non-CF patients compared with the
USA where the study was carried out.
In the early stage of lung colonisation, migration of CF-
pathogens mainly occurs in a downward direction from the
more permanent focus in the sinuses towards the lungs [24].
This migration occurs more frequently during the viral season
where the nasal secretions are more liqueﬁed [91]. The results
in paper [4] further support this theory, as it may be concluded
that if sinus surgery and adjuvant therapy reduce the frequencies
of lower-airway bacteria, the sinuses are bound to inﬂuence the
lower airways by downward migration of bacteria. Moreover,
when evaluating the literature on this subject, including the
previous papers from our group, I ﬁnd it unquestionable
that the sinuses play an important role in causing pulmonary
colonisations and infections. It is more debateable what can be
done to eliminate this risk of colonisation.
There is empirical evidence that the persistent sinus bacteria are
facilitated by inﬂamed tissue obstructing the sinus ostia, lower
antibiotic concentration than in the lungs due to lower blood
perfusion in the sinus mucosa, that the infection is localised
as an empyema in the sinuses and maybe also as intramucosal
abscesses. Furthermore, our previous research [24] has shown
that the bacteria develop resistant genotypes and phenotypes in
the sinuses. In contrast to the nasal environment, where CF-
polyps show various patterns of neutrophil-dominated acute and
chronic inﬂammation [153], we found a reduced number of
PMNs surrounding the bioﬁlms on the sinus mucosa compared
with the lungs. All these points taken together with our
results that the upper airways are dominated by the non-
phlogistic IgA [1,2], may explain the mechanism of why sinus
bacteria are more persistent than in the lungs. In essence, what
is important for the clearance of intermittent P. aeruginosa
colonisation in the CF lungs is only partially functional in the
sinuses, providing opportunities for the bacteria to adapt through
evolution of resistance mechanisms.
Some non-infected CF patients were solely colonised with CF-
pathogens in the sinuses [4]. It is likely that this represented
their initial colonisation. Nevertheless, we cannot prove that
these patients beneﬁted from the treatment, and it is challenging
to determine the prevalence of how often the colonisations
initiated in the sinuses. We are conﬁdent that our prospective
study on speciﬁc IgA in sputum and nasal secretions will prove
useful in diagnosing P. aeruginosa sinusitis and thereby come
closer to a conclusion. In fact, after we ended this study [2]),
two of the four patients from the non-infected group with
the highest IgA levels became intermittently lung-colonised
with P. aeruginosa , suggesting that they were already sinus-
colonised at the time of the study.
According to the Leeds criteria, CF-patients are cabable of
having P. aeruginosa sinusitis but being categorised as being
free from P. aeruginosa (non-infected) [17]. In my opinion, it
would be clinically relevant to characterise CF infections both
according to their sino-nasal bacteriology and according to the
lower-airway colonisations/infections. This will require more
focus on treating the upper airways, a general collaboration with
ORLs, and that clinicians bear in mind that non-BAL lower-
airway samples can be cross-contaminated from the upper
airways. Furthermore, in order to characterise CF infections and
select the right CF patients for FESS, it is essential to ﬁnd a
combination of tests that can diagnose CF-pathogenic sinusitis
with high sensitivity. Nasal lavage, as described by Mainz [71]
or in [2], is a very easy way to obtain samples with little patient
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discomfort. However, these samples also contain bacteria from
the upper pharynx and thereby do not solely represent sinus
bacteria. It is also uncertain if saline from nasal irrigations
represent material from all sinuses. In unpublished data, we
have found a relatively low positive predictive value when
doing middle meatus cultures in early intermittently colonised
patients not previously having sinus surgery, which makes us
conclude that this test cannot stand by itself. However, IgA
can easily be obtained and quantiﬁed by ELISA, and if this
is combined with regularly obtained cultures from the middle
meatus, cultures from nasal irrigations and other paraclinical
measures like serum antibodies and pulmonary function, we
believe it has a high diagnostic value.
It may also be clinically relevant to subdivide intermittently
colonised patients based on the colonisation pattern and bacteria
genotypes as previously described [24]: (a) patients with single
or multiple events of short colonisation periods (<6 months)
followed by eradication; (b) intermittently colonised patients
with multiple recurrent colonisation events with the same
genotype of bacteria and a low systemic immune response [1];
(c) patients with a rapid development of chronic lung infections
with increasing precipitating antibodies. Thus, it is most likely
that intermittently colonised patients from group b have an
additional sinonasal infectious focus. This would help us to
select patients for upper-airway treatment by FESS and/or
conservative treatment.
Though we have shown that nearly all chronically infected CF
patients have CF-pathogens in their sinuses, which in some
cases could be eradicated [3,4]), we did not expect that they
would have a signiﬁcant decrease in positive lower-airway
cultures [4]). In particular, four chronically infected patients
had a pronounced effect of the treatment and we put forward the
theory that such patients could be false-positive categorised if
the lower-airway samples are cross-contaminated by the upper
airways. Thus, the result of true chronically infected patients
having an effect of the treatment is more uncertain. However,
it is accepted that the lung damage in CF patients with chronic
infections characteristically is focal [154] leading to a focal loss
of alveoles and an annual decline of lung function of about
1–2% [78]. In that way, true chronically infected patients may
beneﬁt from having their sinus bacteria eradicated, as it may
prevent further spread of the infection by aspiration from the
sinuses to new areas of the lungs [155].
It can be argued that in paper [3] and [4] we gave no answers
as to whether the same results could have been achieved
by conservative treatment comprising nasal irrigations and
endoscopical cleansing. Studies on otherwise healthy patients
with CRS have shown that an ostial dimension should be>4mm
to ensure that irrigations penetrate the maxillary sinus, and that
the frontal sinuses are more difﬁcult to irrigate [156,157]. By
comparison, when using nebulizers the dimension requirements
are thought to be smaller [139,158]. Literature addressing nasal
irrigations in CF patients mainly focus on the maxillary sinuses,
but one should remember that CF patients may have frontal
sinuses, which contain CF-pathogens as often as the maxillary
sinuses (paper [3] and unpublished data). To ensure permanent
(a) (b)
Fig. 12. Two methods of doing postoperatively nasal irrigations. (Nicely
demonstrated by the author’s 10-year-old son Bertram).
drainage from the sinuses adequate extensive surgery may
be considered; this could comprise a modiﬁed endoscopic
medial maxillectomy [128] or a Draf III [130], the latter
ensuring drainage from the frontal sinuses, which are the most
challenging sinuses to operate. We advocate that it is important
to ensure permanent access to the sinuses, both to reduce
symptoms of CRS but also to facilitate postoperative treatment
preventing sinus infections and spread of bacteria to the lungs.
We agree that more extensive surgery is needed in CF patients
than in patients without CF, but have to await studies on
FESS comparing surgical methods with postoperative clinical
examinations, symptoms, adverse effects and cultures.
In paper [3] and in section 2.8, the possibilities of using differ-
ent or additional ways to treat the upper airways are summarised
but the most optimal combination is not yet deﬁned. In addition,
a synergistic effect has been suggested when using tobramycin
and colistimethate sodium for inhalation, thus, this should also
be considered when doing research on which drugs to use for
nasal irrigations/nebulizations [159]. Especially when aiming
at eradicating A. xylosoxidans and B. cepacia complex, one
must be aware of their antibiotic susceptibility (described in sec-
tion 2.4). While others have described a good effect of nebuliz-
ers such as the PARI sinus [139], the patients in our study have
been able to choose between two devices for nasal irrigations
(Fig. 12). We have no conﬂicts of interest and ﬁnd the device in
Fig. 12a creates a higher pressure than the one in Fig. 12b, thus
the saline being more likely to penetrate the sinuses.
Finally, based on our ﬁndings, I want to stress the importance
of focussing on upper airway bacteriology in CF patients,
especially in the outpatient routine treatment and the importance
of guidelines for upper-airway treatment being established. This
requires collaboration between the CF physicians, microbiolo-
gists and ORLs.
6.1. Study strength and weaknesses
Themajor strength of our set-up is the establishment of a unique,
effective, collaboration focusing on CF; the microbiologists and
CF physicians have had a strong collaboration through many
years. This project has allowed ORLs to be a part of this
collaboration making it multidisciplinary. We have a very large
group of CF patients, which are all seen on a monthly basis,
which is very frequent compared with other CF centres. This
results in an abundance of systematically collected data that can
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be evaluated for the beneﬁt of the CF patients. The patients seem
very committed to the research, the adherence is high, and only
two patients did not wish to be enrolled in the IgA study [2])
and only one patient turned down the offer of FESS [4]). The
willingness to attend the postoperative controls and return the
questionnaires was also high (80–99%).
A project is always strengthened by having one single
committed coordinator; this improves adherence and reduces
bias. To maintain and develop our high quality of treatment, I
ﬁnd it necessary that the ORLs are keep on seeing CF patients,
evaluating their CRS symptoms, doing endonasal endoscopy
and sino-nasal cultures. Furthermore, it is also important that the
CF physicians on a standardized basis ask for CRS symptoms
and focus on possible upper airway infections.
The main outcome of our four studies reported in [1–4] is based
on culture results and antibody measurements. The Department
of Clinical Microbiology has few, but very dedicated and
experienced, laboratory technicians who are responsible for
doing the bacterial and antibody CF analyses. Thus, the
possibility of inter-observer errors is low.
In paper [2], a weakness is that the study was not prospective;
that is why our hypothesis that high IgA actually reﬂects
sinus colonisations cannot be ﬁnally proven. IgA against
alginate can, in small concentrations, be present in non-infected
individuals and IgA against St-Ag can cross-react with other
Gram-negative bacteria and the test is therefore not totally
speciﬁc towards P. aeruginosa [19,160]. Even if our theory
is correct, one should bear in mind that it only should be
used as a supplementary test creating awareness of possible
colonisations.
In paper [3], a drawback might be that due to ethical
considerations, only a minority of the postoperative samples
were taken during general anaesthesia, which is why false
negative culture results from the sinuses cannot be excluded.
However, I was the only one who obtained the samples, the
majority of patients had persistent opening to their sinuses,
and the follow-up procedure was standardized. Except when
doing FESS, the same point applies in all our studies where one
can always discuss how representative the material is. There
are advantages and disadvantages in concern of doing regular
culture compared with molecular methods; these two methods
will be compared in an upcoming paper from our group. In
short, the true positive diagnostic value is high using both
methods. Though the molecular methods in a few cases did
detect CF-pathogens missed by conventional culture methods,
a case was also seen where the abundance of different sinonasal
bacteria resulted in a false-negative result of CF-pathogens
by the molecular methods. Sinus samples could in both cases
become cross-contaminated by bacteria from the anterior nasal
cavity, but we ﬁnd this fact clinically unimportant. What is
important is that cross-contamination of lower-airway samples
from the upper airways remains as a potential confounder.
Hence, when the CF-pathogen bacteria were eradicated from the
upper airways, there would be a smaller risk of false-positive
lower-airway culture results.
Regardless of cross-contamination, CF-patients who do not
show growth of CF pathogens for a longer period will get their
antibiotic treatment reduced. Consequently, we could have anal-
ysed whether the use of antibiotics decreased as a consequence
of the decreased positive lower-airway cultures, or if unchanged,
if the higher rate of antibiotics compared with positive lower-
airway cultures might have been a confounder. The reason
that this analysis was not included in paper [4] was that we
would have had to differentiate between types of administration
(oral, inhalation and intravenous) and differentiate between
prophylactic, eradication and maintenance therapy. We found
that this would have taken focus from our main outcome.
A general weakness concerning papers [1,3] and [4] is that the
FESS-project was step-wise initiated. As a consequence, at the
beginning of the study period, we were more reluctant including
patients for FESS, making FESS extensive, and encouraging
patients to be thorough with the postoperative treatment. As the
existing research on FESS in CF patients, including the extent
and postoperative treatment, was very sparse, the FESS by itself
has not been a part of the research but solely the outcome of
an established treatment. As a consequence, some CF-patients
with no symptoms of CRS have not been offered FESS as early
as we would now recommend and some not at all. Furthermore,
we have not done surgery so extensive and explored all sinuses
if the symptoms were not present. On the other hand, these facts
ought not to inﬂuence the results in a positive way. What may
weaken the way our results can be interpreted is that we did
not have a control group to the FESS group. Instead we have
to use the knowledge of the natural history of CF. Generally, a
confounder could be that patients’ way of being treated changed
during follow-up, but in our case the treatment strategy has
mainly been unchanged throughout the study period [4].
We are aware that CF patients are a heterogeneous group with
confounders such as different co-morbidities of CF, large age
distribution, different lung infection patterns (including LTX),
and a wide span in the use of medicine. Despite this, we found
it most correct to include all patients; however, this should be
kept in mind when interpreting our results, but we have partly
dealt with the confounders by doing sub-analyses.
Finally, we now stand in a classical dilemma: the need for a
randomized case-control study is in conﬂict with the positive
results from paper [4] and the positive feed-back we have got
from the vast majority of CF patients. This subject has been
discussed with the Head of the Copenhagen Trial Unit, Centre
for Clinical intervention Research. In conclusion, based on
all our summarised results, our studies can be compared to
a “Fase IV clinical trial” [161] and it would be unethical to
randomise CF patients to FESS or no treatment. The next step is
to randomise patients to either conservative treatment, minimal
FESS or extensive FESS, and let the outcomes, especially
postoperative IgAs and lower-airway cultures, be evaluated by
someone blinded to the treatment.
7. Perspectives
The determination that the sinuses play a role in the initial
colonisation and infection in CF patients opens a lot of
unanswered questions and still requires an active role from
ORLs.
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First of all, we do not have the perfect tool to diagnose whether
a CF patient has CF-lung-pathogenic bacteria in their sinuses
without doing sinus surgery. A prospective study of nasal and
saliva IgA against P. aeruginosa must be carried out, as well as
prospective studies concerning cultures of nasal irrigations [71]
compared with meatus media cultures [112] and perioperative
ﬁndings. Research on whether biomarkers as BPI-ANCA [155]
and other inﬂammatory markers can play a role in determining
sinusitis is also advisable.
Secondly, our postoperative treatment have partly been empiric
and based on knowledge from the CF-lungs. Studies involving
animal experiments are recommended to determine the most
suitable drug(s), dose and administration interval for nasal
irrigations.
Thirdly, a prospective trial randomizing CF patients to either
sinus surgery or conservative treatment with nasal antibiotic and
saline irrigation is highly important.
Fourth, using molecular methods such as FISH [78], it will
be interesting to determine the diversity of the bacteria in the
sinuses, the bacteria–bacteria interaction, presence of bioﬁlm,
and how bacteria changes phenotype after sinus surgery. It
will be of clinical interest if certain bacterial phenotypes and
genotypes can be correlated with severity of the disease so
aggressive treatment can be early initiated in these cases.
Finally, in the same way as CF patients, patients with primary
ciliary dyskinesia (PCD) may have sinusitis initiating colonisa-
tion and infection though the mechanisms are different [162].
In general, there is a lack on research on PCD, which is why CF
treatment often is used on this patient group [162]. I recommend
that a study be done on extensive sinus surgery and adjuvant
therapy in PCD patients.
8. Conclusion
With respect to the aims of this study (section 1.1), the following
can be stated:
(a) There is a very high prevalence of CF pathogen sinusitis.
The bacteria persist in the sinuses for years and can be
a focus for initial lung colonisation and maintain the
infection.
(b) In contrast to the lungs, the sinus inﬂammation is dominated
by non-phlogistic speciﬁc IgAs; this facilitates persistence
of bacteria.
(c) There is no single way of diagnosing CF-pathogens in
the sinuses without being invasive. Nasal IgA may be a
surrogate-marker for P. aeruginosa in the lungs and may be
used as a supplementary diagnostic tool for P. aeruginosa-
sinusitis.
(d) We have treated our patients with extensive FESS and stan-
dardized postoperative follow-up, i.v. antibiotics, prolonged
nasal irrigation with saline and antibiotics in addition to
nasal steroids. Further studies are needed to ﬁnd the most
effective treatment.
(e) By this treatment strategy (d), quality of life was improved,
bacterial sinus foci could be eradicated and the frequency
of pulmonary samples positive for CF pathogens could be
reduced. This indicates a reduced CF morbidity.
Altogether, the CF-upper airways should not be neglected and
ORLs can give a signiﬁcant contribution to CF treatment.
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